COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Follow-Up Questions
What is COSCIENS Biopharma Inc (CSCI)'s P/E Ratio?
The P/E ratio of COSCIENS Biopharma Inc is N/A
Who is the CEO of COSCIENS Biopharma Inc?
Mr. Gilles Gagnon is the President of COSCIENS Biopharma Inc, joining the firm since 2000.
What is the price performance of CSCI stock?
The current price of CSCI is 2.6, it has decreased 0% in the last trading day.
What are the primary business themes or industries for COSCIENS Biopharma Inc?
COSCIENS Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is COSCIENS Biopharma Inc market cap?
COSCIENS Biopharma Inc's current market cap is $8.2
Is COSCIENS Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 0 analysts have made analyst ratings for COSCIENS Biopharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
